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Table. Clinical outcomes upto 5-years
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BACKGROUND It has been well known that a major cause of vasospastic angina is
endothelial dysfunction of the coronary artery. Also, renin-angiotensin-aldosterone
system (RAAS) is known to be closely associated with endothelial dysfunction.
However, there is no study for impact of RAAS inhibitor on long-term clinical out-
comes in vasospastic angina patients (pts).
METHODS A total of 3,349 consecutive pts without signiﬁcant coronary artery disease
(CAD) underwent acetylcholine (Ach) provocation test and diagnosed as CAS between
Nov. 2004 and May. 2014 were enrolled. Signiﬁcant CAS was deﬁned as > 70% of
narrowing by incremental intracoronary injection of 20, 50 and 100 mg into left cor-
onary artery. Pts were divided into two groups based on the treat of RAAS inhibitors
(the RAAS group: n¼666, the control group; n¼2683). To adjust potential con-
founders, a propensity score matched (PSM) analysis was performed using the logistic
regression model.
RESULTS After PSM analysis, 2 propensity-matched groups (1,143 pairs, n ¼ 2,286, C-
statistic¼0.845) were generated and the baseline characteristics of the two groups
were balanced. At 5 years, despite of similar incidence of individual hard endpoints
including mortality, myocardial infarction and revascularization, the RAAS inhibitors
group were signiﬁcantly associated with lower incidence of recurrent angina
requiring repeat coronary angiography than the control group (HR; 0.63, 95% C.I;
0.40-0.99, p¼0.048, Table and Figure).
CONCLUSIONS In our study, RAAS inhibitor was associated with reduced
incidence of recurrent angina in pts with vasospastic angina up to 5-year clinical
follow-up.CRT-138
Impact of Trimetazidine Treatment on 5-year Clinical Outcomes in Patients with
Signiﬁcant Coronary Artery Spasm; A Propensity Score Matching Study
Seung-Woon Rha,1 Byoung Geol Choi,2 Se Yeon Choi,1 Ji Young Park,3 Sang-Ho Park,4
Jihun Ahn,5 Woong Gil Choi,6 Soo Hyun Kim,6 Eun-Gyu Lee,7 Sang Yeub Lee,8
Sang Min Kim,8 Min Woong Kim,9 Seong Gyu Yoon,2 Tae Hoon Ahn,10 Dong Joo Oh1
1Cardiovascular Center, Korea University Guro Hospital, Seoul, Korea, Republic of;
2Department of Medicine, Korea University Graduate School, Seoul, Korea, Republic of;
3Cardiology Department, Eulji General Hospital, Seoul, Korea, Republic of; 4Cardiology
Department, Soonchunhyang University Cheonan Hospital, Cheonan, Korea, Republic
of; 5Department of Internal Medicine, Soonchunhyang University Gumi Hospital,
Gumi, Korea, Republic of; 6Division of Cardiology, Konkuk University Chungju
Hospital, Chungju, Korea, Republic of; 7Cardiovascular Cencer, Andong Sungso
Hospital, Andong, Korea, Republic of; 8Cardiovascular Center, Chungbuk National
University Hospital, Cheongju, Korea, Republic of; 9Department of Cardiology,
Hanyang University Medical Center, Hanmaeum Hospital, Changwon, Korea, Republic
of; 10Gachon University of Medicine and Science, Gil Hospital, Incheon, Korea,
Republic of
BACKGROUND Trimetazidine (VastinanTM) is an anti-ischemic metabolic agent,
which improves myocardial glucose utilization through inhibition of fatty acid
metabolism, also known as fatty acid oxidation inhibitor. Trimetazidine usually
prescribed as a long-term treatment of angina pectoris. The aim of this study is
to investigate clinical impact of trimetazidine as an additional treatment of acetyl-
choline (Ach) induced coronary artery spasm (CAS) on clinical outcomes up to
ﬁve-years.
METHODS A total of 3,360 consecutive patients (pts) underwent Ach provocation
test and positive CAS pts were enrolled between Nov. 2004 and May. 2014. Sig-
niﬁcant CAS was deﬁned as > 70% of narrowing by incremental intracoronary in-
jection of 20, 50 and 100 mg into left coronary artery. Pts were divided into two
groups: the Trimetazidine group (DiltiazemþNitrateþTrimetazidine; n¼1,154), the
control group (DiltiazemþNitrateþPlacebo; n¼745). To adjust potential confounders,
a propensity score matched (PSM) analysis was performed using the logistic
regression model.
RESULTS After PSM analysis, 2 propensity-matched groups (659 pairs, n ¼1,318, C-
statistic¼0.695) were generated and the baseline characteristics of the two groups
were balanced. At 5 years, there were similar incidence of individual hard endpoints
including mortality, myocardial infarction, revascularization and recurrent angina
requiring repeat coronary angiography.
CONCLUSIONS In this study, despite the expected improvement if ischemic symp-
toms by anti-ischemic mechanisms, an additional treatment with Trimetazidine in
CAS pts was not associated with improving clinical outcomes up to ﬁve-years. To get a
ﬁnal conclusion, a large scale randomized trial would be needed.
Table. Clinical Outcomes up to 5-years after Propensity Score Matching
